Hang Y - Search Results

1

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Sevigny J, et al. Among authors: hang y. Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323. Nature. 2016. PMID: 27582220 Updated.

2

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. Sevigny J, et al. Among authors: hang y. Nature. 2017 Jun 21;546(7659):564. doi: 10.1038/nature22809. Nature. 2017. PMID: 28640269

3

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.

Diao L, Hang Y, Othman AA, Nestorov I, Tran JQ. Diao L, et al. Among authors: hang y. Clin Pharmacokinet. 2016 Aug;55(8):943-55. doi: 10.1007/s40262-016-0366-7. Clin Pharmacokinet. 2016. PMID: 26873229 Clinical Trial.

4

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients.

Hang Y, Hu X, Zhang J, Liu S, Deykin A, Nestorov I. Hang Y, et al. J Pharmacokinet Pharmacodyn. 2016 Aug;43(4):371-83. doi: 10.1007/s10928-016-9477-x. Epub 2016 Jun 14. J Pharmacokinet Pharmacodyn. 2016. PMID: 27299457 Free PMC article. Clinical Trial.

5

Population-Based Pharmacokinetic and Exposure-Efficacy Analyses of Peginterferon Beta-1a in Patients With Relapsing Multiple Sclerosis.

Hu X, Hang Y, Cui Y, Zhang J, Liu S, Seddighzadeh A, Deykin A, Nestorov I. Hu X, et al. Among authors: hang y. J Clin Pharmacol. 2017 Aug;57(8):1005-1016. doi: 10.1002/jcph.883. Epub 2017 Apr 10. J Clin Pharmacol. 2017. PMID: 28394418 Free PMC article. Clinical Trial.

6

Population PK-PD analyses of CD25 occupancy, CD56^bright NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis.

Diao L, Hang Y, Othman AA, Mehta D, Amaravadi L, Nestorov I, Tran JQ. Diao L, et al. Among authors: hang y. Br J Clin Pharmacol. 2016 Nov;82(5):1333-1342. doi: 10.1111/bcp.13051. Epub 2016 Aug 3. Br J Clin Pharmacol. 2016. PMID: 27333593 Free PMC article.

7

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.

Ahamadi M, Mehrotra N, Hanan N, Lai Yee K, Gheyas F, Anton J, Bani M, Boroojerdi B, Smit H, Weidemann J, Macha S, Thuillier V, Chen C, Yang M, Williams-Gray CH, Stebbins GT, Pagano G, Hang Y, Marek K, Venuto CS, Javidnia M, Dexter D, Pedata A, Stafford B, Akalu M, Stephenson D, Romero K, Sinha V; Critical Path for Parkinson’s Consortium. Ahamadi M, et al. Among authors: hang y. Clin Pharmacol Ther. 2021 Aug;110(2):508-518. doi: 10.1002/cpt.2277. Epub 2021 Jun 12. Clin Pharmacol Ther. 2021. PMID: 33894056

8

Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients.

Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ Jr, Wenning L. Rizk ML, et al. Among authors: hang y. Antimicrob Agents Chemother. 2012 Jun;56(6):3101-6. doi: 10.1128/AAC.06417-11. Epub 2012 Mar 19. Antimicrob Agents Chemother. 2012. PMID: 22430964 Free PMC article. Clinical Trial.

9

Characterizing Effects of Antidiabetic Drugs on Heart Rate, Systolic and Diastolic Blood Pressure.

Maringwa J, Sardu ML, Hang Y, Czerniak R, Vishnubhotla M, Vakilynejad M, Pfister M. Maringwa J, et al. Among authors: hang y. Clin Pharmacol Ther. 2021 Jun;109(6):1583-1592. doi: 10.1002/cpt.2130. Epub 2020 Dec 23. Clin Pharmacol Ther. 2021. PMID: 33280092

10

Discrimination of three commercial tuna species through species-specific peptides: From high-resolution mass spectrometry discovery to MRM validation.

Hu L, Zhu Y, Zhong C, Cai Q, Zhang H, Zhang X, Yao Q, Hang Y, Ge Y, Hu Y. Hu L, et al. Among authors: hang y. Food Res Int. 2024 Jul;187:114462. doi: 10.1016/j.foodres.2024.114462. Epub 2024 May 3. Food Res Int. 2024. PMID: 38763689

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

536 results

Search Page